Futura Medical Plc (Futura Medical) specializes in developing and globally commercializing innovative sexual health products. The company's primary activities include the research, development, and commercialization of topically delivered gel formulations to improve sexual health. Futura Medical operates in the healthcare industry, focusing on sexual health products, with its lead product being Eroxon, a treatment for erectile dysfunction (ED).

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Futura Medical's research and development (R&D) initiatives are a cornerstone of the company's strategic growth and innovation in the sexual health market. The company is committed to expanding its portfolio of products and extending product ranges while being mindful of costs. This approach is integral to the company's growth strategy, focusing on delivering clinically proven sexual health products that enhance quality of life. The R&D team at Futura Medical is highly innovative and experienced, leveraging their expertise to broaden the Eroxon range and develop new products. The team has gained unique knowledge in the underserved over the counter (OTC) sexual health category, enabling the identification of product extensions and exploration of new market segments. In FY2024, Futura Medical focused on exploring range extensions and developing innovative products within the sexual health category to meet further unmet demand. The development of Eroxon Intense and WSD4000, a topical treatment for sexual dysfunction in women, highlights the R&D team's ongoing efforts and the exciting opportunities these products present. The company has made significant progress with two new products advancing through their development pipeline. Eroxon Intense is designed to provide a stronger sensation for men, while WSD4000 addresses sexual dysfunction in women. These developments are supported by clinical data and are part of Futura's strategy to meet further unmet demand. Overall, Futura Medical's R&D initiatives are focused on leveraging expertise to innovate and expand product offerings, addressing the growing needs within the OTC sexual health market. In FY2024, the company invested GBP1.7 million in research and development, accounting for 12.2% of its revenue.